Galapagos discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in clinical development in multiple diseases. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and available to patients in Europe, Great Britain and Japan (under a collaboration with Gilead) for rheumatoid arthritis.
Watch our CEO explain the 10-year partnership with Gilead.
We are conducting clinical trials in several inflammatory indications, fibrosis, kidney and metabolic diseases.